Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Artrya Limited ( (AU:AYA) ) has issued an update.
Artrya Limited announced the successful completion of its Share Purchase Plan (SPP), which was significantly oversubscribed, raising approximately A$8.7 million in applications. The company scaled back the eligible applications to raise A$5 million, issuing 2,438,872 new shares. This strong support follows a previous A$75 million placement, reflecting robust investor confidence in Artrya’s market positioning and growth prospects.
The most recent analyst rating on (AU:AYA) stock is a Buy with a A$3.51 price target. To see the full list of analyst forecasts on Artrya Limited stock, see the AU:AYA Stock Forecast page.
More about Artrya Limited
Artrya Limited is an Australian medical technology company focused on developing AI-powered solutions for the detection and management of coronary artery disease. Their proprietary software analyzes coronary CT scans to identify key biomarkers of heart disease, aiding clinicians in accurate and efficient diagnosis. Artrya is committed to advancing cardiac care through innovative technology, with ongoing regulatory and commercial activities in key international markets.
Average Trading Volume: 638,140
Technical Sentiment Signal: Buy
Current Market Cap: A$339.3M
Find detailed analytics on AYA stock on TipRanks’ Stock Analysis page.